1,2 By specifically binding to the key hormone GLP-1, it regulates blood glucose levels and lipid metabolism
When the question becomes ipamorelin vs tesamorelin for recovery and longevity, the CJC-1295/Ipamorelin combination wins clearly
In a Phase 2 NEJM-published trial (2023, n=338, 48 weeks), retatrutide at the highest dose produced mean body weight reduction of approximately 24% in adults with obesity
Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis
Cell culture studies demonstrate that GLP3 exhibits differential potency across its three target receptors: it is approximately 8.9-fold more potent at the human GIP receptor (EC50: 0.0643 nM) compared to the endogenous GIP ligand, while showing reduced potency at GLP-1 receptors (0.4-fold, EC50: 0.775 nM) and glucagon receptors (0.3-fold, EC50: 5.79 nM) relative to their native hormones[3]